Ecotec puts remote methane detection into pockets with the Gazoscan Mini
COVENTRY, United Kingdom, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Ecotec is excited to announce a new methane detection device designed to improve worker safety and operational efficiency. The new Gazoscan Mini offers a portable, cost-effective solution for daily use by field operators.
Traditionally, companies have had to choose between low-cost, reactive tools that alert workers once they're already in a methane zone and higher-cost, specialist systems that can be inappropriate for daily use or fixed to a single location. While both types of tools remain important for methane detection, Ecotec developed the Gazoscan Mini in response to demand from midstream customers for a proactive solution that can be deployed by every operator across their sites.
The Gazoscan Mini is compact and lightweight, enabling field workers to carry it easily throughout their shifts. It's powerful enough to detect methane at distances of up to 15 meters, allowing workers to identify potential leaks from a safe distance. This enables frequent inspections, such as daily spot checks, to support and inform quarterly or annual leak detection cycles.
'With the Gazoscan Mini, our industry now has the ability to deploy laser methane detection in the hands of every operator,' says Kyle Jantzen, VP of Business Development, New Products, at Archrock. 'And the move towards an operational approach to leak detection provides a safer and more efficient environment.'
By making methane detection part of daily workflows, the device is designed to help reduce gas loss and minimize downtime by allowing earlier identification of leaks.
Product development has taken place at Ecotec's headquarters in Colton, CA, where the instruments are manufactured, with much of the testing being carried out at operational sites in Texas. The Gazoscan Mini is certified as intrinsically safe and has been tested for use in tough environments.
Ecotec has provided rugged gas analysis instruments and data management to landfill and biogas sectors for 40 years, with subsidiaries in Europe and South America offering global supply and support to a range of sectors. The company's methane monitoring credentials are now established in the oil and gas industry, where leaking methane represents a lost product, as well as a safety and environmental risk.
Discover more at www.ecotecco.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/83805f18-1340-49a6-9fb6-11e31426bb50
[email protected]
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
EROAD Showcases Global Innovation and Expanding Partnerships at Landmark Fleet Day; Strengthens Position as a Leading Telematics Partner
SAN DIEGO, Aug. 6, 2025 /PRNewswire/ -- EROAD (NZX: ERD, ASX: ERD), a global leader in connected fleet management, compliance, and safety solutions, reinforced its technology leadership and commitment at its record-setting 10th Annual Fleet Day, Australasia's largest and most influential fleet event. With participation from more than 1,400 industry leaders, EROAD's Fleet Day stands as a global platform for technological innovation, strategic partnerships, and vision for the future of transportation. "Fleet Day is more than a conference, it's a global forum where industry comes together, innovation accelerates, and the future of safe, sustainable, and profitable transport is shaped," said Mark Heine, co-CEO, EROAD. "The incredible growth of this event are proof of EROAD's momentum in delivering game-changing value for our customers and investors worldwide." Accelerating Customer Value Through Strategic Global Partnerships EROAD announced major expansions to its global partnership ecosystem - delivering seamless integration, actionable data, and faster time-to-value for global fleets. By collaborating with best-in-class industry leaders rather than developing every component in-house, EROAD equips customers with the freedom and flexibility to optimize their operations. "EROAD isn't just keeping up, we're setting the pace. Our vision is clear: to build a platform that makes compliance automatic, safety intelligent, and operational performance undeniable," said David Kenneson, co-CEO, EROAD. "As we continue to expand our ecosystem by partnering with global leaders instead of developing everything internally, we accelerate innovation and unlock rapid benefits for our customers and solve real problems at scale." EROAD also unveiled enhanced collaborations with HERE Technologies and Geotab. EROAD and HERE Technologies have jointly launched a vehicle-aware navigation app tailored for professional fleets, featuring advanced turn-by-turn guidance, innovative safety features, and bridge strike avoidance for high-profile vehicles. New features for the Geotab-powered Etrack Locate solution now support EV monitoring (state of charge, battery health), automated eRUC, driver authentication, and regulatory compliance for heavy vehicles. The ecosystem further expands with a Fleetpal integration for defect management and engine diagnostics, and Whip Around's workflow tools - offering customers unified control and insight across their entire operation. Relentless Focus on Product Innovation EROAD announced the commercial launch its flagship Cold Chain Assurance Solution in New Zealand, ensuring fleets can achieve FSMA-compliant temperature traceability, audit-ready reporting, and seamless cold chain and fuel tax compliance - all in a single automated ecosystem. Attendees also previewed upcoming releases, including a new in-cab driver experience, custom analytics and dashboards, and next-generation driver safety scorecards. Advances in video telematics with Clarity Edge will soon offer 360-degree vision - including side and rear cameras - setting a new standard for risk reduction and driver protection. "EROAD's ecosystem delivers the integrated compliance confidence, operational insight, and future-ready innovation that global fleets demand," said Mark Davidson, Chief Product Officer. A Premier Global Event Driving Transportation Forward With expert panels, live technology showcases, and growing engagement, EROAD's Fleet Day has become a global stage for the fleet, transport, and technology communities. EROAD's ability to convene the industry, launch cutting-edge solutions, and demonstrate worldwide scale cements its position as a global telematics leader and trusted partner. For more information and solutions built for North American fleets, visit About EROAD EROAD (NZX/ASX: ERD) is a hardware-enabled SaaS company delivering safety, compliance, sustainability and efficiency solutions for complex vehicles fleets. Its connected platform is used by commercial and government operators across New Zealand, Australia and North America to manage vehicles, assets and drivers with greater visibility and control. EROAD supports demanding, highly regulated fleet operations, including those moving food, concrete and aggregates, enabling them to operate smarter, safer and more sustainably. EROAD's platform is built on a foundation of regulatory expertise, having delivered the world's first GPS-based road user charging system in New Zealand, where it remains the market leader today. View original content to download multimedia: SOURCE EROAD
Yahoo
2 hours ago
- Yahoo
Is Novo Nordisk Stock a Buy, Sell, or Hold Before Q2 Earnings?
Danish pharmaceutical giant Novo Nordisk A/S (NVO) is facing serious headwinds. After enjoying a strong run fueled by demand for its obesity treatments, the obesity drug pioneer is now under pressure from rising competition, particularly from Eli Lilly's (LLY) weight-loss drugs, as well as trial setbacks for its next-generation therapies. In fact, things took a sharp turn on July 29, when the company cut its full-year sales growth guidance for the second time in just three months and named a new CEO. The market response was swift and brutal, with NVO shares plunging over 21% in a single day. Now, with second-quarter earnings just around the corner on Aug. 6, does Novo Nordisk's recent plunge present a golden buying opportunity, or is it a clear signal to keep your distance? More News from Barchart Dear Nvidia Stock Fans, Mark Your Calendars for August 27 Options Traders Expected Palantir Stock's Tamest Earnings Reaction in a Year. Did They Get It Right? Tesla Gains on Elon Musk's New Pay Package. Is TSLA Stock a Buy? Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! About Novo Nordisk Stock Best known for its blockbuster weight-loss drugs Ozempic and Wegovy, Novo Nordisk is a global healthcare leader with a long-standing focus on chronic disease. Founded in 1923 and headquartered in Denmark, the company has built a strong foundation in diabetes care while expanding its reach into obesity and other severe health conditions. The company commands a market capitalization of about $217.9 billion. While Novo Nordisk has been a trailblazer in the obesity drug market, its stock has hit a rough patch. Softer demand for its blockbuster drugs, combined with intensifying competition in the weight-loss space, has taken a toll on investor sentiment. The stock has tumbled a staggering 66% from its 52-week high of $139.74 reached in August 2024, and it's currently down 44.7% year-to-date (YTD). In stark contrast, the broader S&P 500 Index ($SPX) has managed to notch a gain of approximately 7.1% over the same period, while its rival Eli Lilly has seen only a marginal drop so far this year, highlighting just how far Novo has fallen out of favor with the market. Given its underwhelming price action, Novo Nordisk stock is starting to look like a value play. Currently trading at just 12.5 times forward earnings, it's priced well below the sector median of 16.87x, and dramatically lower than its own five-year average of 30.92x. Novo Nordisk's Q1 Earnings Snapshot In early May, Novo Nordisk posted a solid first-quarter earnings report for fiscal 2025, but the shine was dulled by a cautious outlook. Total revenue climbed 19% year-over-year (YOY) to 78.1 billion Danish kroner, powered by a massive 85% surge in Wegovy sales, which hit 17.4 billion Danish kroner. Ozempic also continued to perform, with sales rising 18% to 32.7 billion Danish kroner. Profits also impressed, with net profit climbing 14% to 29 billion Danish kroner, while operating profit increased 22% to 38.8 billion Danish kroner. But despite these promising numbers, Novo trimmed its full-year sales growth and operating profit growth guidance, citing 'lower-than-planned penetration of branded GLP-1 treatments in the US.' The company pointed to the growing presence of U.S. compounding pharmacies, which have been legally producing copycat versions of Wegovy and Ozempic under an FDA-approved exemption for addressing drug shortages. That growing parallel market has begun to chip away at Novo's momentum. On a more promising note, the company completed its REDEFINE 2 trial during the quarter, with its next-generation drug CagriSema delivering an impressive 15.7% weight loss in patients with obesity or overweight conditions and type 2 diabetes. Novo plans to file for its first regulatory approval in early 2026, potentially marking the next significant chapter in its obesity pipeline. Novo Nordisk Slashes Guidance Again and Names New CEO On July 29, Novo Nordisk held a conference call that left investors rattled, as it unveiled major leadership changes and another sharp downgrade to its 2025 financial outlook. The company slashed its full-year sales growth guidance to 8%-14%, down from the previously expected 13%-21%. Operating profit growth was also revised lower, now projected at 10%-16% compared to May's forecast of 16%-24%. The revised outlook sent a strong signal that Novo is bracing for a more challenging year ahead. A big part of the pressure comes from its obesity blockbuster, Wegovy. In its update, Novo pointed to several headwinds weighing on U.S. sales, including the continued rise of compounded GLP-1 knockoffs, slower-than-expected market expansion, and increasing competition. These challenges have clouded the outlook for one of Novo's key growth drivers, sparking concerns about whether the company can maintain its dominance in the rapidly growing weight-loss market. Adding to the uncertainty, Novo also announced a leadership shake-up. Maziar Mike Doustdar, the current EVP of international operations, will take over as CEO on Aug. 7, succeeding Lars Fruergaard Jørgensen, whose surprise resignation was announced in May. The transition comes at a pivotal moment, with the company under pressure to protect market share and reignite growth amid shifting dynamics in the obesity drug landscape. What Do Analysts Think About Novo Nordisk Stock? Despite all the swirling uncertainty, there's still a hint of optimism in the air. With Novo Nordisk set to unveil its Q2 earnings on Aug. 6 and a new CEO stepping in shortly after, Wall Street hasn't lost faith, with analysts leaning cautiously bullish, giving the stock a consensus rating of 'Moderate Buy' overall. Of the 19 analysts offering recommendations, seven advise a 'Strong Buy,' nine suggest a 'Hold,' one advocates a 'Moderate Sell,' and the remaining two maintain a 'Strong Sell.' NVO's average analyst price target of $71.75 suggests 47% potential upside from current levels. However, the Street-high target of $112 implies that shares can rally as much as 129.5% from current price levels. On the date of publication, Anushka Mukherji did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
2 hours ago
- Yahoo
Why Novo Nordisk Stock Slipped Today
Key Points It was a double miss for the Wegovy maker in its second quarter. It's been hammered not only by competing licensed drugs, but it also has to contend with copycats. 10 stocks we like better than Novo Nordisk › Novo Nordisk (NYSE: NVO) stock imitated the company's leading product on Wednesday by slimming down in price. The Danish pharmaceutical's shares lost nearly 4% of their value following its latest earnings release, comparing unfavorably to the modest (0.7%) gain of the S&P 500 index. Still growing, but... Novo Nordisk, famous for its Wegovy obesity drug (and its sibling, diabetes treatment Ozempic), unveiled its first half and second quarter of 2025 figures early Wednesday morning. For the quarter, the company booked 76.9 billion Danish kroner ($11.9 billion) in revenue, which was up only marginally on a sequential basis, and 13% higher compared to the same period of 2024. Net income, meanwhile, was down from the previous quarter but up from the year-ago quarter. It rose by 32% year over year to 26.5 billion kroner ($4.1 billion), or 5.96 kroner ($0.92) per share. Both headline numbers missed the consensus analyst estimates, although not by much. Pundits tracking the company were modeling the equivalent of just under $12 billion for revenue, and $0.95 per share on the bottom line. Although Novo Nordisk continues to post double-digit increases thanks largely to Wegovy and Ozempic, it has been in the investor doghouse so far this month. That's because at the end of July, it significantly cut its guidance for both total sales and operating profit. Withering competition Much of this has to do with the intense competition Novo Nordisk is facing due to the runaway success of those medications. These days, pharmacy sector powerhouse Eli Lilly is doing brisk business with a directly competing product, Zepbound, while third parties are copying Wegovy's semaglutide molecule for their own compounded products. The company announced no fewer than 14 new lawsuits on Tuesday, making a total of 146 across 40 U.S. states, to combat the latter. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $619,036!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,092,648!* Now, it's worth noting Stock Advisor's total average return is 1,026% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Why Novo Nordisk Stock Slipped Today was originally published by The Motley Fool
